Optimal management of bladder cancer requires an accurate, standardised and timely pathological diagnosis, and close communication between surgeons and pathologists. Here, we provide an update on pathology reporting standards of transurethral resections of the bladder and cystectomies.
We reviewed recent literature, focusing on developments between 2013 and 2021.
Published reporting standards developed by pathology organizations have improved diagnosis and treatment. Tumor sub-staging and subtyping has gained increased attention. Lymph nodes continue to be an area of debate, and their staging has seen minor modifications. Several tasks, particularly regarding specimen preparation ("grossing"), are not yet standardized and offer opportunity for improvement. Molecular classification is rapidly evolving, but currently has only limited impact on management.
Pathological reporting of bladder cancer is continuously evolving and remains challenging in some areas. This review provides an overview of recent major developments, with a particular focus on published reporting standards.
World journal of urology. 2021 Sep 23 [Epub ahead of print]
Eva Compérat, André Oszwald, Gabriel Wasinger, Donna E Hansel, Rodolfo Montironi, Theodorus van der Kwast, Johannes A Witjes, Mahul B Amin
Department of Pathology, Hôpital Tenon, Sorbonne University, Paris VI, Paris, France. ., Department of Pathology, General Hospital, Vienna Medical University, Vienna, Austria., Department of Pathology and Laboratory Medicine, School of Medicine, Oregon Health and Science University, Portland, OR, USA., Department of Pathology, School of Medicine, United Hospitals, Polytechnic University of the Marche Region, Ancona, Italy., Department of Pathology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada., Department of Urology, Radboudumc, Nijmegen, The Netherlands., Department of Pathology and Laboratory Medicine and Urology, University of Tennessee Health Science, Memphis, TN, USA.